{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:41:56Z","timestamp":1791322916773,"version":"4.3.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12016-016-8591-2","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T09:41:07Z","timestamp":1479721267000},"page":"287-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["An Update on the Use of Immunomodulators in Primary Immunodeficiencies"],"prefix":"10.1007","volume":"52","author":[{"given":"Pandiarajan","family":"Vignesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-2892","authenticated-orcid":false,"given":"Amit","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"8591_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fimmu.2014.00162","volume":"5","author":"W Al-Herz","year":"2014","unstructured":"Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang ML (2014) Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 5:162. doi: 10.3389\/fimmu.2014.00162","journal-title":"Front Immunol"},{"issue":"10","key":"8591_CR2","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciu646","volume":"59","author":"C Aguilar","year":"2014","unstructured":"Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, Pellier I, Stephan JL et al (2014) Prevention of infections during primary immunodeficiency. Clin Infect Dis 59(10):1462\u20131470. doi: 10.1093\/cid\/ciu646","journal-title":"Clin Infect Dis"},{"issue":"5","key":"8591_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/BOR.0b013e32835680c6","volume":"24","author":"TP Atkinson","year":"2012","unstructured":"Atkinson TP (2012) Immune deficiency and autoimmunity. Curr Opin Rheumatol 24(5):515\u2013521. doi: 10.1097\/BOR.0b013e32835680c6","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"8591_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaci.2009.10.022","volume":"124","author":"LM Griffith","year":"2009","unstructured":"Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O\u2019Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT (2009) Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 124(6):1152\u20131160 . doi: 10.1016\/j.jaci.2009.10.022 e12","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8591_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/MOP.0b013e32834cd67a","volume":"23","author":"C Booth","year":"2011","unstructured":"Booth C, Gaspar HB, Thrasher AJ (2011) Gene therapy for primary immunodeficiency. Curr Opin Pediatr 23(6):659\u2013666. doi: 10.1097\/MOP.0b013e32834cd67a","journal-title":"Curr Opin Pediatr"},{"key":"8591_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fimmu.2014.00627","volume":"5","author":"H Chapel","year":"2014","unstructured":"Chapel H, Prevot J, Gaspar HB, Espa\u00f1ol T, Bonilla FA, Solis L, Drabwell J (2014) Primary immune deficiencies\u2014principles of care. Front Immunol 5:627. doi: 10.3389\/fimmu.2014.00627","journal-title":"Front Immunol"},{"issue":"9","key":"8591_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","volume":"74","author":"NM Haar ter","year":"2015","unstructured":"ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T et al (2015) Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636\u20131644. doi: 10.1136\/annrheumdis-2015-207546","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8591_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/annrheumdis-2014-206580","volume":"74","author":"S Federici","year":"2015","unstructured":"Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, Kon\u00e9-Paut I, Dewarrat N, Cantarini L, Insalaco A, Uziel Y, Rigante D (2015) Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 74(5):799\u2013805. doi: 10.1136\/annrheumdis-2014-206580","journal-title":"Ann Rheum Dis"},{"key":"8591_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621\u2013668. doi: 10.1146\/annurev.immunol.25.022106.141627","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"8591_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrrheum.2013.101","volume":"9","author":"G Grateau","year":"2013","unstructured":"Grateau G, Hentgen V, Stojanovic KS, J\u00e9ru I, Amselem S, Steichen O (2013) How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol 9(10):624\u2013629. doi: 10.1038\/nrrheum.2013.101","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"8591_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clim.2013.03.016","volume":"147","author":"A Almeida de Jesus","year":"2013","unstructured":"Almeida de Jesus A, Goldbach-Mansky R (2013) Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 147(3):155\u2013174. doi: 10.1016\/j.clim.2013.03.016","journal-title":"Clin Immunol"},{"issue":"5","key":"8591_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2015.02.037","volume":"135","author":"J Chinen","year":"2015","unstructured":"Chinen J, Notarangelo LD, Shearer WT (2015) Advances in basic and clinical immunology in 2014. J Allergy Clin Immunol 135(5):1132\u20131141. doi: 10.1016\/j.jaci.2015.02.037","journal-title":"J Allergy Clin Immunol"},{"key":"8591_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12763","volume":"1356","author":"PJ Maglione","year":"2015","unstructured":"Maglione PJ, Simchoni N, Cunningham-Rundles C (2015) Toll-like receptor signaling in primary immune deficiencies. Ann N Y Acad Sci 1356:1\u201321. doi: 10.1111\/nyas.12763","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"8591_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/ni.2284","volume":"13","author":"MG Netea","year":"2012","unstructured":"Netea MG, Wijmenga C, O\u2019Neill LAJ (2012) Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 13(6):535\u2013542. doi: 10.1038\/ni.2284","journal-title":"Nat Immunol"},{"issue":"2","key":"8591_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/imm.12143","volume":"140","author":"R Perales-Linares","year":"2013","unstructured":"Perales-Linares R, Navas-Martin S (2013) Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology 140(2):153\u2013167. doi: 10.1111\/imm.12143","journal-title":"Immunology"},{"issue":"7426","key":"8591_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature11583","volume":"491","author":"FG Lafaille","year":"2012","unstructured":"Lafaille FG, Pessach IM, Zhang S-Y, Ciancanelli MJ, Herman M, Abhyankar A, Ying SW, Keros S, Goldstein PA, Mostoslavsky G, Ordovas-Montanes J, Jouanguy E et al (2012) Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 491(7426):769\u2013773. doi: 10.1038\/nature11583","journal-title":"Nature"},{"issue":"8","key":"8591_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJM19910221324080","volume":"324","author":"The International Chronic Granulomatous Disease Cooperative Study Group","year":"1991","unstructured":"The International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324(8):509\u2013516. doi: 10.1056\/NEJM19910221324080","journal-title":"N Engl J Med"},{"issue":"4","key":"8591_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF01957365","volume":"154","author":"RS Weening","year":"1995","unstructured":"Weening RS, Leitz GJ, Seger RA (1995) Recombinant human interferon-gamma in patients with chronic granulomatous disease\u2014European follow up study. Eur J Pediatr 154(4):295\u2013298. doi: 10.1007\/BF01957365","journal-title":"Eur J Pediatr"},{"issue":"1","key":"8591_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12016-009-8136-z","volume":"38","author":"SM Holland","year":"2010","unstructured":"Holland SM, Chronic granulomatous disease (2010) Clin Rev Allergy Immunol 38(1):3\u201310. doi: 10.1007\/s12016-009-8136-z","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"8591_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1006\/bcmd.1995.0028","volume":"21","author":"LS Bemiller","year":"1995","unstructured":"Bemiller LS, Roberts DH, Starko KM, Curnutte JT (1995) Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol Dis 21(3):239\u2013247. doi: 10.1006\/bcmd.1995.0028","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"8591_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1086\/422993","volume":"39","author":"BE Marciano","year":"2004","unstructured":"Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, Malech HL, Gallin JI, Holland SM (2004) Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 39(5):692\u2013699. doi: 10.1086\/422993","journal-title":"Clin Infect Dis"},{"issue":"9","key":"8591_CR22","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood.V89.9.3396","volume":"89","author":"A Ahlin","year":"1997","unstructured":"Ahlin A, Elinder G, Palmblad J (1997) Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 89(9):3396\u20133401","journal-title":"Blood"},{"issue":"4","key":"8591_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.intimp.2012.01.016","volume":"12","author":"F Naderi beni","year":"2012","unstructured":"Naderi beni F, Fattahi F, Mirshafiey A, Ansari M, Mohsenzadegan M, Movahedi M, Pourpak Z, Moin M (2012) Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. Int Immunopharmacol 12(4):689\u2013693. doi: 10.1016\/j.intimp.2012.01.016","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"8591_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/157489108786242378","volume":"3","author":"PR Errante","year":"2008","unstructured":"Errante PR, Fraz\u00e3o JB, Condino-Neto A (2008) The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov 3(3):225\u2013230. doi: 10.2174\/157489108786242378","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"1","key":"8591_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5114\/ceji.2015.50833","volume":"40","author":"S Filiz","year":"2015","unstructured":"Filiz S, Uygun DFK, K\u00f6ksoy S, \u015eahin E, Ye\u011fin O (2015) In vitro interferon \u03b3 improves the oxidative burst activity of neutrophils in patients with chronic granulomatous disease with a subtype of gp91phox deficiency. Cent Eur J Immunol 40(1):54\u201360. doi: 10.5114\/ceji.2015.50833","journal-title":"Cent Eur J Immunol"},{"issue":"6","key":"8591_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cell.2004.11.038","volume":"119","author":"MG Gutierrez","year":"2004","unstructured":"Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V (2004) Autophagy is a defense mechanism inhibiting BCG and mycobacterium tuberculosis survival in infected macrophages. Cell 119(6):753\u2013766. doi: 10.1016\/j.cell.2004.11.038","journal-title":"Cell"},{"issue":"5792","key":"8591_CR27","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1126\/science.1129577","volume":"313","author":"SB Singh","year":"2006","unstructured":"Singh SB, Davis AS, Taylor GA, Deretic V (2006) Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 313(5792):1438\u20131441. doi: 10.1126\/science.1129577","journal-title":"Science"},{"issue":"5","key":"8591_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10875-015-0173-1","volume":"35","author":"VK Sharma","year":"2015","unstructured":"Sharma VK, Pai G, Deswarte C, Lodha R, Singh S, Kang LW, Yin CC, Casanova JL, Bustamante J, Kabra SK (2015) Disseminated Mycobacterium avium complex infection in a child with partial dominant interferon gamma receptor 1 deficiency in India. J Clin Immunol 35(5):459\u2013462. doi: 10.1007\/s10875-015-0173-1","journal-title":"J Clin Immunol"},{"issue":"1","key":"8591_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2014.01.004","volume":"151","author":"K Takeda","year":"2014","unstructured":"Takeda K, Kawai T, Nakazawa Y, Komuro H, Shoji K, Morita K, Katsuta T, Yamamoto M, Miyairi I, Ohya Y, Ishiguro A, Onodera M (2014) Augmentation of antitubercular therapy with IFN\u03b3 in a patient with dominant partial IFN\u03b3 receptor 1 deficiency. Clin Immunol 151(1):25\u201328. doi: 10.1016\/j.clim.2014.01.004","journal-title":"Clin Immunol"},{"key":"8591_CR30","doi-asserted-by":"publisher","first-page":"691956","DOI":"10.1155\/2011\/691956","volume":"2011","author":"AA Alangari","year":"2011","unstructured":"Alangari AA, Al-Zamil F, Al-Mazrou A, Al-Muhsen S, Boisson-Dupuis S, Awadallah S, Kambal A, Casanova JL (2011) Treatment of disseminated mycobacterial infection with high-dose IFN-\u03b3 in a patient with IL-12R\u03b21 deficiency. Clin Dev Immunol 2011:691956. doi: 10.1155\/2011\/691956","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"8591_CR31","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood-2015-05-645077","volume":"127","author":"V Sheikh","year":"2016","unstructured":"Sheikh V, Porter BO, DerSimonian R, Kovacs SB, Thompson WL, Perez-Diez A, Freeman AF, Roby G, Mican J, Pau A, Rupert A, Adelsberger J et al (2016) Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. Blood 127(8):977\u2013988. doi: 10.1182\/blood-2015-05-645077","journal-title":"Blood"},{"issue":"12","key":"8591_CR32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/BF01957224","volume":"152","author":"H Azuma","year":"1993","unstructured":"Azuma H, Sakata H, Saijyou M, Okuno A (1993) Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr 152(12):998\u20131000","journal-title":"Eur J Pediatr"},{"issue":"8","key":"8591_CR33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/PL00008395","volume":"159","author":"H Azuma","year":"2000","unstructured":"Azuma H, Oshima M, Ito K, Okuno A, Kawabata I, Banba K, Murahashi H, Sekine T, Kato Y, Ikebuchi K, Ikeda H (2000) Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Eur J Pediatr 159(8):633\u2013634","journal-title":"Eur J Pediatr"},{"issue":"4","key":"8591_CR34","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1172\/JCI44862","volume":"121","author":"JS Orange","year":"2011","unstructured":"Orange JS, Roy-Ghanta S, Mace EM, Maru S, Rak GD, Sanborn KB, Fasth A, Saltzman R, Paisley A, Monaco-Shawver L, Banerjee PP, Pandey R (2011) IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest 121(4):1535\u20131548. doi: 10.1172\/JCI44862","journal-title":"J Clin Invest"},{"issue":"1","key":"8591_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/gut.42.1.127","volume":"42","author":"B Myrup","year":"1998","unstructured":"Myrup B, Valerius NH, Mortensen PB (1998) Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 42(1):127\u2013130","journal-title":"Gut"},{"issue":"5","key":"8591_CR36","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaci.2005.01.016","volume":"115","author":"J Wang","year":"2005","unstructured":"Wang J, Mayer L, Cunningham-Rundles C (2005) Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease. J Allergy Clin Immunol 115(5):1092\u20131094. doi: 10.1016\/j.jaci.2005.01.016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8591_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/BOR.0000000000000059","volume":"26","author":"NM Ter Haar","year":"2014","unstructured":"Ter Haar NM, Frenkel J (2014) Treatment of hereditary autoinflammatory diseases. Curr Opin Rheumatol 26(3):252\u2013258. doi: 10.1097\/BOR.0000000000000059","journal-title":"Curr Opin Rheumatol"},{"issue":"23","key":"8591_CR38","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426\u20132437. doi: 10.1056\/NEJMoa0807865","journal-title":"N Engl J Med"},{"issue":"3","key":"8591_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2249.2011.04533.x","volume":"167","author":"R Goldbach-Mansky","year":"2012","unstructured":"Goldbach-Mansky R (2012) Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 167(3):391\u2013404. doi: 10.1111\/j.1365-2249.2011.04533.x","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"8591_CR40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/ard.2003.016014","volume":"63","author":"SB Cohen","year":"2004","unstructured":"Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062\u20131068. doi: 10.1136\/ard.2003.016014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8591_CR41","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"HM Hoffman","year":"2012","unstructured":"Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34(10):2091\u20132103. doi: 10.1016\/j.clinthera.2012.09.009","journal-title":"Clin Ther"},{"issue":"8","key":"8591_CR42","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/art.23620","volume":"58","author":"R Goldbach-Mansky","year":"2008","unstructured":"Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopaulos JH, Weinstein SP, Mellis SJ, Kastner DL (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58(8):2432\u20132442. doi: 10.1002\/art.23620","journal-title":"Arthritis Rheum"},{"issue":"23","key":"8591_CR43","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416\u20132425. doi: 10.1056\/NEJMoa0810787","journal-title":"N Engl J Med"},{"issue":"9","key":"8591_CR44","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1073\/pnas.1322831111","volume":"111","author":"A Luca de","year":"2014","unstructured":"de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, Begun J, Plantinga TS, Joosten LA, van der Meer JW, Chamilos G, Netea MG et al (2014) IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A 111(9):3526\u20133531. doi: 10.1073\/pnas.1322831111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8591_CR45","first-page":"95","volume":"69","author":"FL Veerdonk van de","year":"2011","unstructured":"van de Veerdonk FL, Netea MG, Dinarello CA, van der Meer JWM (2011) Anakinra for the inflammatory complications of chronic granulomatous disease. Neth J Med 69(2):95","journal-title":"Neth J Med"},{"issue":"12","key":"8591_CR46","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schaffer AA, Gruning BA, Unger S, Frede N et al (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20(12):1410\u20131416. doi: 10.1038\/nm.3746","journal-title":"Nat Med"},{"issue":"1","key":"8591_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaci.2015.08.036","volume":"137","author":"S Lee","year":"2016","unstructured":"Lee S, Moon JS, Lee C-R, Kim H-E, Baek S-M, Hwang S, Kang GH, Seo JK, Shin CH, Kang HJ, Ko JS, Park SG, Choi M (2016) Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol 137(1):327\u2013330. doi: 10.1016\/j.jaci.2015.08.036","journal-title":"J Allergy Clin Immunol"},{"issue":"6246","key":"8591_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","volume":"349","author":"B Lo","year":"2015","unstructured":"Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, Marsh R, Husami A, Kissell D et al (2015) AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349(6246):436\u2013440. doi: 10.1126\/science.aaa1663","journal-title":"Science"},{"issue":"1","key":"8591_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10875-015-0224-7","volume":"36","author":"OK Alkhairy","year":"2016","unstructured":"Alkhairy OK, Abolhassani H, Rezaei N, Fang M, Andersen KK, Chavoshzadeh Z, Mohammadzadeh I, El-Rajab MA, Massaad M, Chou J, Aghamohammadi A, Geha RS et al (2016) Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol 36(1):33\u201345. doi: 10.1007\/s10875-015-0224-7","journal-title":"J Clin Immunol"},{"key":"8591_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.micpath.2015.09.003","volume":"94","author":"G Hajishengallis","year":"2016","unstructured":"Hajishengallis G, Moutsopoulos NM (2016) Role of bacteria in leukocyte adhesion deficiency-associated periodontitis. Microb Pathog 94:21\u201326. doi: 10.1016\/j.micpath.2015.09.003","journal-title":"Microb Pathog"},{"issue":"229","key":"8591_CR51","doi-asserted-by":"publisher","first-page":"229ra40","DOI":"10.1126\/scitranslmed.3007696","volume":"6","author":"NM Moutsopoulos","year":"2014","unstructured":"Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N, Abusleme L, Zenobia C, Hosur KB, Abe T, Uzel G, Chen W et al (2014) Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med 6(229):229ra40. doi: 10.1126\/scitranslmed.3007696","journal-title":"Sci Transl Med"},{"issue":"8","key":"8591_CR52","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2014-01-546713","volume":"123","author":"DT Teachey","year":"2014","unstructured":"Teachey DT (2014) Targeting cytokines in ALPS: it\u2019s FAShionable. Blood 123(8):1116\u20131118. doi: 10.1182\/blood-2014-01-546713","journal-title":"Blood"},{"issue":"4","key":"8591_CR53","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","volume":"125","author":"JD Milner","year":"2015","unstructured":"Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, Lyons JJ, Engelhardt KR, Zhang Y, Topcagic N, Roberson ED, Matthews H et al (2015) Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125(4):591\u2013599. doi: 10.1182\/blood-2014-09-602763","journal-title":"Blood"},{"issue":"24","key":"8591_CR54","doi-asserted-by":"publisher","first-page":"20037","DOI":"10.18632\/oncotarget.5042","volume":"6","author":"J Wienke","year":"2015","unstructured":"Wienke J, Janssen W, Scholman R, Spits H, van Gijn M, Boes M, van Montfrans J, Moes N, de Roock S (2015) A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation. Oncotarget 6(24):20037\u201320042. doi: 10.18632\/oncotarget.5042","journal-title":"Oncotarget"},{"issue":"1","key":"8591_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12115","volume":"175","author":"YJ Crow","year":"2014","unstructured":"Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI (2014) Therapies in Aicardi-Gouti\u00e8res syndrome. Clin Exp Immunol 175(1):1\u20138. doi: 10.1111\/cei.12115","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"8591_CR56","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/rheumatology\/keu524","volume":"54","author":"K Put","year":"2015","unstructured":"Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona S, Fallarino F, De Somer L et al (2015) Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3. Rheumatology (Oxford) 54(8):1507\u20131517. doi: 10.1093\/rheumatology\/keu524","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8591_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P (2004) An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104(3):735\u2013743. doi: 10.1182\/blood-2003-10-3413","journal-title":"Blood"},{"issue":"Suppl 1","key":"8591_CR58","doi-asserted-by":"publisher","first-page":"O68","DOI":"10.1186\/1546-0096-13-S1-O68","volume":"13","author":"C Bracaglia","year":"2015","unstructured":"Bracaglia C, Gatto A, Pardeo M, Lapeyre G, Ferlin W, Nelson R, de Min C, De Benedetti F (2015) Anti interferon-gamma (IFN\u03b3) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Pediatr Rheumatol Online J 13(Suppl 1):O68. doi: 10.1186\/1546-0096-13-S1-O68","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"8591_CR59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.33416","volume":"64","author":"AC Bulua","year":"2012","unstructured":"Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, Ward MM, Yarboro CH, Kastner DL, Siegel RM, Hull KM (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64(3):908\u2013913. doi: 10.1002\/art.33416","journal-title":"Arthritis Rheum"},{"issue":"7","key":"8591_CR60","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s10875-014-0079-3","volume":"34","author":"TJ Franxman","year":"2014","unstructured":"Franxman TJ, Howe LE, Baker JR (2014) Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol 34(7):820\u2013827. doi: 10.1007\/s10875-014-0079-3","journal-title":"J Clin Immunol"},{"issue":"1","key":"8591_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ajg.2008.72","volume":"104","author":"DJB Marks","year":"2009","unstructured":"Marks DJB, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW (2009) Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn\u2019s disease. Am J Gastroenterol 104(1):117\u2013124. doi: 10.1038\/ajg.2008.72","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"8591_CR62","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1086\/657308","volume":"51","author":"G Uzel","year":"2010","unstructured":"Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM (2010) Complications of tumor necrosis factor-\u03b1 blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 51(12):1429\u20131434. doi: 10.1086\/657308","journal-title":"Clin Infect Dis"},{"issue":"1","key":"8591_CR63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10875-012-9755-3","volume":"33","author":"NM Chase","year":"2013","unstructured":"Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, Singh S, Shahir KS, Tisol WB, Nugent ML, Rao RN, Mackinnon AC et al (2013) Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 33(1):30\u201339. doi: 10.1007\/s10875-012-9755-3","journal-title":"J Clin Immunol"},{"issue":"1","key":"8591_CR64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s10875-012-9778-9","volume":"33","author":"J-N Boursiquot","year":"2013","unstructured":"Boursiquot J-N, G\u00e9rard L, Malphettes M, Fieschi C, Galicier L, Boutboul D, Borie R, Viallard JF, Soulas-Sprauel P, Berezne A, Jaccard A, Hachulla E et al (2013) Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 33(1):84\u201395. doi: 10.1007\/s10875-012-9778-9","journal-title":"J Clin Immunol"},{"issue":"4","key":"8591_CR65","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","volume":"155","author":"D Gobert","year":"2011","unstructured":"Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A et al (2011) Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 155(4):498\u2013508. doi: 10.1111\/j.1365-2141.2011.08880.x","journal-title":"Br J Haematol"},{"issue":"1","key":"8591_CR66","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2141.2007.06616.x","volume":"138","author":"JJ Kim","year":"2007","unstructured":"Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM (2007) Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 138(1):94\u201396. doi: 10.1111\/j.1365-2141.2007.06616.x","journal-title":"Br J Haematol"},{"issue":"1","key":"8591_CR67","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jaci.2013.01.040","volume":"132","author":"H Toyoda","year":"2013","unstructured":"Toyoda H, Azuma E, Kawasaki Y, Iwasa T, Ohashi H, Otsuki S, Iwamoto S, Hirayama M, Itoh-Habe N, Wada H, Kondo M, Keida Y, Ito T, Komada Y (2013) Cord blood transplantation combined with rituximab for Wiskott-Aldrich syndrome with autoimmune thrombotic thrombocytopenic purpura. J Allergy Clin Immunol 132(1):226\u2013227. doi: 10.1016\/j.jaci.2013.01.040","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8591_CR68","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3109\/08880018.2013.792893","volume":"30","author":"S Emir","year":"2013","unstructured":"Emir S, Vezir E, Azkur D, Demir HA, Metin A (2013) Characteristics of children with non-hodgkin lymphoma associated with primary immune deficiency diseases: descriptions of five patients. Pediatr Hematol Oncol 30(6):544\u2013553. doi: 10.3109\/08880018.2013.792893","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"8591_CR69","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jcp.56.7.555","volume":"56","author":"NJ Sebire","year":"2003","unstructured":"Sebire NJ, Haselden S, Malone M, Davies EG, Ramsay AD (2003) Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol 56(7):555\u2013557. doi: 10.1136\/jcp.56.7.555","journal-title":"J Clin Pathol"},{"issue":"1","key":"8591_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOP.0b013e32834ea739","volume":"24","author":"DT Teachey","year":"2012","unstructured":"Teachey DT (2012) New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 24(1):1\u20138. doi: 10.1097\/MOP.0b013e32834ea739","journal-title":"Curr Opin Pediatr"},{"issue":"17","key":"8591_CR71","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2011-12-395707","volume":"119","author":"SK Browne","year":"2012","unstructured":"Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, Pancholi MJ, Yang LM, Priel DL, Uzel G, Freeman AF, Hayes CE et al (2012) Anti-CD20 (rituximab) therapy for anti\u2013IFN-\u03b3 autoantibody\u2013associated nontuberculous mycobacterial infection. Blood 119(17):3933\u20133939. doi: 10.1182\/blood-2011-12-395707","journal-title":"Blood"},{"issue":"8","key":"8591_CR72","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","volume":"190","author":"LB Rosen","year":"2013","unstructured":"Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, Suputtamongkol Y, Bennett JE, Pyrgos V, Williamson PR, Ding L, Holland SM et al (2013) Anti-granulocyte-macrophage colony stimulating factor autoantibodies in patients with cryptococcal meningitis. J Immunol 190(8):3959\u20133966. doi: 10.4049\/jimmunol.1202526","journal-title":"J Immunol"},{"issue":"35","key":"8591_CR73","doi-asserted-by":"publisher","first-page":"13009","DOI":"10.1073\/pnas.0806874105","volume":"105","author":"I Gavanescu","year":"2008","unstructured":"Gavanescu I, Benoist C, Mathis D (2008) B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: a therapeutic approach for APECED patients. Proc Natl Acad Sci U S A 105(35):13009\u201313014. doi: 10.1073\/pnas.0806874105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"8591_CR74","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.4161\/mabs.36292","volume":"6","author":"RR Beerli","year":"2014","unstructured":"Beerli RR, Bauer M, Fritzer A, Rosen LB, Buser RB, Hanner M, Maudrich M, Nebenfuehr M, Toepfer JAS, Mangold S, Bauer A, Holland SM et al (2014) Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma. MAbs 6(6):1608\u20131620. doi: 10.4161\/mabs.36292","journal-title":"MAbs"},{"issue":"5","key":"8591_CR75","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s10875-012-9691-2","volume":"32","author":"A Branellec","year":"2012","unstructured":"Branellec A, Bouillet L, Javaud N, Mekinian A, Boccon-Gibod I, Blanchard-Delaunay C, Oksenhendler E, Ollivier Y, Dunogu\u00e9 B, Amarger S, Ponard D, Drouet C et al (2012) Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol 32(5):936\u2013941. doi: 10.1007\/s10875-012-9691-2","journal-title":"J Clin Immunol"},{"issue":"6","key":"8591_CR76","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/ndtplus\/sfp109","volume":"2","author":"A Lionet","year":"2009","unstructured":"Lionet A, Prov\u00f4t F, Glowacki F, Fr\u00e9meaux-Bacchi V, Hazzan M (2009) A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2(6):458\u2013460. doi: 10.1093\/ndtplus\/sfp109","journal-title":"NDT Plus"},{"issue":"6","key":"8591_CR77","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/cid\/cit809","volume":"58","author":"CA Czaja","year":"2014","unstructured":"Czaja CA, Merkel PA, Chan ED, Lenz LL, Wolf ML, Alam R, Frankel SK, Fischer A, Gogate S, Perez-Velez CM, Knight V (2014) Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-\u03b3 autoantibody. Clin Infect Dis 58(6):e115\u2013e118. doi: 10.1093\/cid\/cit809","journal-title":"Clin Infect Dis"},{"issue":"5","key":"8591_CR78","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M et al (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85(5):1151\u20131160. doi: 10.1038\/ki.2013.373","journal-title":"Kidney Int"},{"issue":"7","key":"8591_CR79","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrclinonc.2010.40","volume":"7","author":"MP Strout","year":"2010","unstructured":"Strout MP, Seropian S, Berliner N (2010) Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 7(7):415\u2013420. doi: 10.1038\/nrclinonc.2010.40","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8591_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pbc.24188","volume":"60","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence J, Mo JQ, Bleesing JJ, Filipovich AH, Jordan MB (2013) Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 60(1):101\u2013109. doi: 10.1002\/pbc.24188","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"8591_CR81","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, R\u00f6th A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233\u20131243. doi: 10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"issue":"25","key":"8591_CR82","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25):6786\u20136792. doi: 10.1182\/blood-2011-02-333997","journal-title":"Blood"},{"issue":"23","key":"8591_CR83","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169\u20132181. doi: 10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"issue":"8","key":"8591_CR84","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","volume":"208","author":"L Liu","year":"2011","unstructured":"Liu L, Okada S, Kong X-F, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B et al (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208(8):1635\u20131648. doi: 10.1084\/jem.20110958","journal-title":"J Exp Med"},{"issue":"2","key":"8591_CR85","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","volume":"135","author":"E Higgins","year":"2015","unstructured":"Higgins E, Al Shehri T, McAleer MA, Conlon N, Feighery C, Lilic D, Irvine AD (2015) Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135(2):551\u2013553. doi: 10.1016\/j.jaci.2014.12.1867","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8591_CR86","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, Lee CC, DeMattia MA et al (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371(6):507\u2013518. doi: 10.1056\/NEJMoa1312625","journal-title":"N Engl J Med"},{"issue":"13","key":"8591_CR87","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA, Cheng C, Kurachi M, Levine R, Wherry EJ, Canna SW, Behrens EM, Nichols KE (2016) Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127(13):1666\u20131675. doi: 10.1182\/blood-2015-12-684399","journal-title":"Blood"},{"issue":"1","key":"8591_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12016-015-8466-y","volume":"50","author":"P Li","year":"2016","unstructured":"Li P, Huang P, Yang Y, Hao M, Peng H, Li F (2016) Updated understanding of autoimmune lymphoproliferative syndrome (ALPS). Clin Rev Allergy Immunol 50(1):55\u201363. doi: 10.1007\/s12016-015-8466-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"8591_CR89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fped.2015.00065","volume":"3","author":"VK Rao","year":"2015","unstructured":"Rao VK (2015) Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome. Front Pediatr 3:65. doi: 10.3389\/fped.2015.00065","journal-title":"Front Pediatr"},{"issue":"1","key":"8591_CR90","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","volume":"127","author":"KL Bride","year":"2016","unstructured":"Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT (2016) Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 127(1):17\u201328. doi: 10.1182\/blood-2015-07-657981","journal-title":"Blood"},{"issue":"2","key":"8591_CR91","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jpeds.2005.04.017","volume":"147","author":"L Bindl","year":"2005","unstructured":"Bindl L, Torgerson T, Perroni L, Youssef N, Ochs HD, Goulet O, Ruemmele FM (2005) Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 147(2):256\u2013259. doi: 10.1016\/j.jpeds.2005.04.017","journal-title":"J Pediatr"},{"key":"8591_CR92","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","volume":"3","author":"F Barzaghi","year":"2012","unstructured":"Barzaghi F, Passerini L, Bacchetta R (2012) Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol 3:211. doi: 10.3389\/fimmu.2012.00211","journal-title":"Front Immunol"},{"key":"8591_CR93","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13011","author":"R Bacchetta","year":"2016","unstructured":"Bacchetta R, Barzaghi F, Roncarolo MG (2016) From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. doi: 10.1111\/nyas.13011","journal-title":"Ann N Y Acad Sci"},{"issue":"6160","key":"8591_CR94","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O et al (2013) Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Science 342(6160):866\u2013871. doi: 10.1126\/science.1243292","journal-title":"Science"},{"issue":"1","key":"8591_CR95","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M, Stoddard J, Ouyang W et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency. Nat Immunol 15(1):88\u201397. doi: 10.1038\/ni.2771","journal-title":"Nat Immunol"},{"issue":"11","key":"8591_CR96","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.1074\/jbc.M110.202911","volume":"286","author":"J Harris","year":"2011","unstructured":"Harris J, Hartman M, Roche C, Zeng SG, O\u2019Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA et al (2011) Autophagy controls IL-1\u03b2 secretion by targeting pro-IL-1\u03b2 for degradation. J Biol Chem 286(11):9587\u20139597. doi: 10.1074\/jbc.M110.202911","journal-title":"J Biol Chem"},{"issue":"1","key":"8591_CR97","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1172\/JCI71471","volume":"124","author":"AE Bigorgne","year":"2014","unstructured":"Bigorgne AE, Farin HF, Lemoine R, Mahlaoui N, Lambert N, Gil M, Schulz A, Philippet P, Schlesser P, Abrahamsen TG, Oymar K, Davies EG et al (2014) TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest 124(1):328\u2013337. doi: 10.1172\/JCI71471","journal-title":"J Clin Invest"},{"issue":"17","key":"8591_CR98","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","volume":"114","author":"HB Gaspar","year":"2009","unstructured":"Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD (2009) How I treat ADA deficiency. Blood 114(17):3524\u20133532. doi: 10.1182\/blood-2009-06-189209","journal-title":"Blood"},{"issue":"2","key":"8591_CR99","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","volume":"117","author":"B Chan","year":"2005","unstructured":"Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB (2005) Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 117(2):133\u2013143. doi: 10.1016\/j.clim.2005.07.006","journal-title":"Clin Immunol"},{"issue":"12","key":"8591_CR100","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.4049\/jimmunol.1001770","volume":"185","author":"F Serana","year":"2010","unstructured":"Serana F, Sottini A, Chiarini M, Zanotti C, Ghidini C, Lanfranchi A, Notarangelo LD, Caimi L, Imberti L (2010) The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol 185(12):7713\u20137722. doi: 10.4049\/jimmunol.1001770","journal-title":"J Immunol"},{"issue":"4","key":"8591_CR101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/ped.2014.0425","volume":"27","author":"S Caccia","year":"2014","unstructured":"Caccia S, Suffritti C, Cicardi M (2014) Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol 27(4):159\u2013163. doi: 10.1089\/ped.2014.0425","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"3","key":"8591_CR102","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1586\/eci.10.19","volume":"6","author":"S Krassilnikova","year":"2010","unstructured":"Krassilnikova S, Craig ET, Craig TJ (2010) Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2). Expert Rev Clin Immunol 6(3):327\u2013334. doi: 10.1586\/eci.10.19","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"8591_CR103","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jpeds.2012.11.030","volume":"162","author":"W Lumry","year":"2013","unstructured":"Lumry W, Manning ME, Hurewitz DS, Davis-Lorton M, Fitts D, Kalfus IN, Uknis ME (2013) Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 162(5):1017\u20131022. doi: 10.1016\/j.jpeds.2012.11.030","journal-title":"J Pediatr"},{"issue":"1","key":"8591_CR104","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1684\/ejd.2013.2252","volume":"24","author":"AL Manson","year":"2014","unstructured":"Manson AL, Dempster J, Grigoriadou S, Buckland MS, Longhurst HJ (2014) Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema. Eur J Dermatol 24(1):28\u201334. doi: 10.1684\/ejd.2013.2252","journal-title":"Eur J Dermatol"},{"issue":"14","key":"8591_CR105","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1182\/blood-2013-11-538686","volume":"123","author":"FY Li","year":"2014","unstructured":"Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ (2014) XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123(14):2148\u20132152. doi: 10.1182\/blood-2013-11-538686","journal-title":"Blood"},{"issue":"6142","key":"8591_CR106","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1126\/science.1240094","volume":"341","author":"B Chaigne-Delalande","year":"2013","unstructured":"Chaigne-Delalande B, Li F-Y, O\u2019Connor GM, Lukacs MJ, Jiang P, Zheng L, Shatzer A, Biancalana M, Pittaluga S, Matthews HF, Jancel TJ, Bleesing JJ et al (2013) Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341(6142):186\u2013191. doi: 10.1126\/science.1240094","journal-title":"Science"},{"issue":"22","key":"8591_CR107","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2010-02-272005","volume":"116","author":"R Fernandez-Boyanapalli","year":"2010","unstructured":"Fernandez-Boyanapalli R, Frasch SC, Riches DWH, Vandivier RW, Henson PM, Bratton DL (2010) PPAR\u03b3 activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 116(22):4512\u20134522. doi: 10.1182\/blood-2010-02-272005","journal-title":"Blood"},{"issue":"2","key":"8591_CR108","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jaci.2014.10.034","volume":"135","author":"RF Fernandez-Boyanapalli","year":"2015","unstructured":"Fernandez-Boyanapalli RF, Frasch SC, Thomas SM, Malcolm KC, Nicks M, Harbeck RJ, Jakubzick CV, Nemenoff R, Henson PM, Holland SM, Bratton DL (2015) Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease. J Allergy Clin Immunol 135(2):517\u2013527 . doi: 10.1016\/j.jaci.2014.10.034 e12","journal-title":"J Allergy Clin Immunol"},{"key":"8591_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.01.033","author":"M Migliavacca","year":"2016","unstructured":"Migliavacca M, Assanelli A, Ferrua F, Cicalese MP, Biffi A, Frittoli M, Silvani P, Chidini G, Calderini E, Mandelli A, Camporesi A, Milani R et al (2016) Pioglitazone as a novel therapeutic approach in chronic granulomatous disease. J Allergy Clin Immunol. doi: 10.1016\/j.jaci.2016.01.033","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8591_CR110","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.exphem.2008.12.002","volume":"37","author":"KC Dowdell","year":"2009","unstructured":"Dowdell KC, Pesnicak L, Hoffmann V, Steadman K, Remaley AT, Cohen JI, Straus SE, Rao VK (2009) Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL\/lpr(\u2212\/\u2212) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 37(4):487\u2013494. doi: 10.1016\/j.exphem.2008.12.002","journal-title":"Exp Hematol"},{"issue":"13","key":"8591_CR111","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1182\/blood-2006-04-020610","volume":"108","author":"P Bob\u00e9","year":"2006","unstructured":"Bob\u00e9 P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK (2006) Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice. Blood 108(13):3967\u20133975. doi: 10.1182\/blood-2006-04-020610","journal-title":"Blood"},{"issue":"2","key":"8591_CR112","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/pbc.23144","volume":"57","author":"R Bajwa","year":"2011","unstructured":"Bajwa R, Savelli S, Gross T (2011) Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 57(2):336\u2013337. doi: 10.1002\/pbc.23144","journal-title":"Pediatr Blood Cancer"},{"key":"8591_CR113","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fphar.2015.00262","volume":"6","author":"BZ Shao","year":"2015","unstructured":"Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C (2015) NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol 6:262. doi: 10.3389\/fphar.2015.00262","journal-title":"Front Pharmacol"},{"issue":"3","key":"8591_CR114","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AAB, Chae JJ, Higgins SC, Mu\u00f1oz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21(3):248\u2013255. doi: 10.1038\/nm.3806","journal-title":"Nat Med"},{"issue":"3","key":"8591_CR115","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D\u2019Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL et al (2015) The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21(3):263\u2013269. doi: 10.1038\/nm.3804","journal-title":"Nat Med"},{"issue":"5","key":"8591_CR116","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/pai.12168","volume":"25","author":"AJ MacGinnitie","year":"2014","unstructured":"MacGinnitie AJ (2014) Pediatric hereditary angioedema. Pediatr Allergy Immunol 25(5):420\u2013427. doi: 10.1111\/pai.12168","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"8591_CR117","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jaci.2013.03.026","volume":"132","author":"K Joseph","year":"2013","unstructured":"Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP (2013) Factor XII-independent activation of the bradykinin-forming cascade: implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol 132(2):470\u2013475. doi: 10.1016\/j.jaci.2013.03.026","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8591_CR118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/cei.12379","volume":"178","author":"C Wintenberger","year":"2014","unstructured":"Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, Martin L, Gompel A, Bouillet L (2014) Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178(1):112\u2013117. doi: 10.1111\/cei.12379","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"8591_CR119","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/WOX.0b013e318279affa","volume":"5","author":"T Craig","year":"2012","unstructured":"Craig T, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M et al (2012) WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5(12):182\u2013199. doi: 10.1097\/WOX.0b013e318279affa","journal-title":"World Allergy Organ J"},{"issue":"3","key":"8591_CR120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1034\/j.1399-3038.2002.01014.x","volume":"13","author":"H Farkas","year":"2002","unstructured":"Farkas H, Harmat G, F\u00fcst G, Varga L, Visy B (2002) Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 13(3):153\u2013161","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"8591_CR121","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10875-016-0271-8","volume":"36","author":"TJ Vece","year":"2016","unstructured":"Vece TJ, Watkin LB, Nicholas SK, Canter D, Braun MC, Guillerman RP, Eldin KW, Bertolet G, McKinley SD, de Guzman M, Forbes LR, Chinn I et al (2016) Copa syndrome: a novel autosomal dominant immune dysregulatory disease. J Clin Immunol 36(4):377\u2013387. doi: 10.1007\/s10875-016-0271-8","journal-title":"J Clin Immunol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-016-8591-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T11:55:42Z","timestamp":1601207742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-016-8591-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["8591"],"URL":"https:\/\/doi.org\/10.1007\/s12016-016-8591-2","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}